PRL-3 Inhibitor I (BR-1) is a phosphatase of regenerating liver 3 (PRL-3) inhibitor which blocks the migration and invasion of metastatic cancer cells.

10-Ethenyl-19-norprogesterone (Org OD 02-0) is a selective agonist for the membrane progesterone receptor α (mPRα) with an IC50 of 33.9 nM, known to activate MAPK activity, and inhibit prolactin (PRL) secretion in the pituitary [1] [2].

PRL 3195 is a somatostatin receptor antagonist, exhibiting K i values of 6, 17, 66, 1000, and 1000 nM for human somatostatin receptors sst 5 , sst 2 , sst 3 , sst 1 , and sst 4, respectively [1].

FA-Ala-Arg is a dipeptide featuring a furylacryloyl group that degrades to yield arginine. It augments nitric oxide (NO) synthesis in MCF-7 cells through a mechanism in which cell-surface Carboxypeptidase-D (CPD) elevates intracellular arginine levels. Furthermore, FA-Ala-Arg promotes cell survival in prolactin (PRL)-treated cells wherein PRL modulates CPD mRNA levels [1].

PRL 2915 is a potent antagonist of the human somatostatin subtype 2 receptor (hsst 2), exhibiting a binding affinity (K_i) of 12 nM [1].

Thienopyridone is a potent and selective inhibitor of phosphatase of regenerating liver (PRL) phosphatase(IC50s of 173 nM, 277 nM and 128 nM for PRL-1, PRL-2, and PRL-3, respectively), and induces p130Cas cleavage and apoptosis and has anticancer effects.